Back to discover
Drug

PZ-128

Early clinical development
ClassProteinase-activated receptor 1 inhibitor
RxNorm1941370ChEMBLCHEMBL4297323UNIIIYT6MP4NS9
Proteinase-activated receptor 1
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
PZ-128
RxNorm CUI
1941370
ChEMBL ID
CHEMBL4297323
UNII
IYT6MP4NS9
Primary mechanism
Proteinase-activated receptor 1 inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Proteinase-activated receptor 1
F2R · P25116
INHIBITORProteinase-activated receptor 1 inhibitor

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
2
registered trials across all phases
LATEST COMPLETION 2019
2
Completed
PHASE DISTRIBUTIONn = 2
Phase 11Phase 21
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials